Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma

Table 1 Baseline characteristics of all 132 patients n (%)

Baseline characteristics	Value
Age, yr
> 65	20 (15.2)
≤ 65	112 (84.8)
Gender
Male	121 (91.7)
Female	11 (8.3)
CLIP score
0 or 1	0 (0)
2	38 (28.8)
3	47 (35.6)
4	47 (35.6)
BCLC
A	0 (0)
B	53 (40.2)
C	79 (59.8)
D	0 (0)
ECOG Performance Status
0	87 (65.9)
1	35 (26.5)
2	10 (7.6)
AFP, ng/mL (mean ± SD)	15038.8 ± 22661.5
< 20	27 (20.5)
20-400	23 (17.4)
> 400	82 (62.1)
Tumor nodules
Solitary	110 (83.3)
Multiple	22 (16.7)
Vascular invasion
With	75 (56.8)
Without	57 (43.2)
Extrahepatic metastasis
With	40 (30.3)
Without	92 (69.7)
Child-Pugh stage
A	129 (97.7)
B	3 (2.3)
HBV infection1
Yes	129 (97.7)
No	3 (2.3)
HBV DNA level > 104 copies/mL	50 (37.9)
HCV antibody
Positive	0
Negative	132 (100)
Cirrhosis
With	124 (93.9)
Without	8 (6.1)

¹Patients with chronic hepatitis B history, HBsAg, or anti-HBcAg-positive. AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Group; HBV: Hepatitis B virus; HCV: Hepatitis C virus; SD: Standard deviation.

Table 2 Univariate and multivariate analysis of predictors of tumor progression of all 132 patients

Characteristic	Univariate	Multivariate	HR	95%CI
Age ( ≤ 65 yr >)	0.84
Gender	0.88
Clip score	0.05
BCLC (B, C)	0.02
ECOG (0, 1, 2)	0.59
Cirrhosis	0.79
Solitary or multiple nodules	0.50
Vascular invasion	0.01	0.30	0.75	0.44-1.29
Extrahepatic spread	0.04	0.26	0.73	0.42-1.27
AFP-pre	0.02
< 20 ng/mL		0.05
20-400 ng/mL		0.04	0.55	0.30-0.99
> 400 ng/mL		0.50	1.23	0.67-2.28
HBV DNA > 104 copies/mL	0.66
Gelatin-sponge application	0.26

AFP-pre: Alpha-fetoprotein at baseline; BCLC: Barcelona Clinic Liver Cancer; CI: Confidence interval; ECOG: Eastern Cooperative Group; HBV: Hepatitis B virus; HR: Hazard ratio.

Table 3 Univariate and multivariate analysis of predictors of survival of all 132 patients

Characteristic	Univariate	Multivariate	HR	95%CI
Age ( ≤ 65 yr >)	0.53
Gender	0.46
Clip score	0.29
BCLC (B, C)	0.03
ECOG (0, 1, 2)	0.57
Cirrhosis	0.73
Solitary or multiple nodules	0.74
Vascular invasion	0.00	0.00	2.36	1.41-2.94
Extrahepatic spread	0.04	0.34	1.27	0.78-2.10
AFP-pre	0.02
< 20 ng/mL		0.09
20-400 ng/mL		0.19	0.71	0.43-1.20
> 400 ng/mL		0.22	1.41	0.81-2.49
HBV DNA > 104 copies/mL	0.21
Gelatin-sponge application	0.47

AFP-pre: Alpha-fetoprotein at baseline; BCLC: Barcelona Clinic Liver Cancer; CI: Confidence interval; ECOG: Eastern Cooperative Group; HBV: Hepatitis B virus; HR: Hazard ratio.

Table 4 Tumor responses after treatment of 103 patients

Parameter	n (%)
16-wk disease-control rate	50%
Best response
Complete response	0 (0.0)
Partial response	22 (21.4)
Stable disease	58 (56.3)
Progressive disease	23 (22.3)
AFP response rate (decrease > 25%)	39 (37.9)
No AFP response rate	64 (62.1)
Change < 25%	39 (37.9)
Increase > 25%	25 (24.3)

AFP: Alpha-fetoprotein.